1. GPCR/G Protein
  2. mGluR


Cat. No.: HY-101845 Purity: 98.82%
Handling Instructions

FITM is a negative allosteric modulator of mGlu1 receptor with a Ki of 2.5 nM.

For research use only. We do not sell to patients.
FITM Chemical Structure

FITM Chemical Structure

CAS No. : 932737-65-0

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 177 In-stock
2 mg USD 132 In-stock
5 mg USD 216 In-stock
10 mg USD 312 In-stock
25 mg USD 660 In-stock
50 mg USD 1140 In-stock
100 mg USD 1740 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


FITM is a negative allosteric modulator of mGlu1 receptor with a Ki of 2.5 nM.

IC50 & Target

Ki: 2.5 nM (mGlu1)[1]

In Vitro

FITM fits tightly into the long and narrow pocket. Most of the ligand-receptor interactions are hydrophobic with the exception of the contacts of the pyrimidine-amine group with the T815 7.38 side chain. The mGlu1 binding pocket for FITM largely corresponds to mutagenic data for the common allosteric site in mGlus and likely extends to other class C GPCRs. FITM which shows high affinity and selectivity for mGlu1 over mGlu5[1]. FITM has the high hydrogen bonds occupancy with Thr815 and Tyr805 in dimer A and B of mGlu1 during molecular dynamics simulations. The nitrogen and hydrogen atoms of FITM form the dynamical hydrogen bonds with the hydrogen atom of Tyr805 and oxygen atom of Thr815, respectively. It indicates that there is a strong attraction interaction between FITM and allosteric sites[2].

In Vivo

The pretreatment of rats with unlabeled FITM (1 mg/kg) occupies an mGluR1 binding site of 18F-FITM by more than 99% and does not affect the input function. The Kd (nM) and Bmax (pmol/mL) obtained by the Scatchard analyses with the multidose ligand assays are 2.1 and 36.3, respectively, for the thalamus; 2.1 and 27.5, respectively, for the hippocampus; 1.5 and 22.2, respectively, for the striatum; and 1.5 and 20.5, respectively, for the cingulate cortex with a high confidence[3]. 18F-FITM shows excellent pharmacokinetics, namely the dense and specific accumulation in mGlu1-positive melanomas versus mGlu1-negative hepatoma and normal tissues. Furthermore, the accumulation levels of radioactivity corresponded to the extent of tumor and to levels of mGlu1 protein expression in melanomas and melanoma metastasis[4].

Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 2.6923 mL 13.4615 mL 26.9230 mL
5 mM 0.5385 mL 2.6923 mL 5.3846 mL
10 mM 0.2692 mL 1.3461 mL 2.6923 mL
Please refer to the solubility information to select the appropriate solvent.
Animal Administration

Rats: Sprague–Dawley rats are treated with different doses of unlabeled FITM (0, 1, 5, or 30 μg/kg or 1 mg/kg) just before a bolus injection of 18F-FITM (17–18 MBq, 30–40 pmol, 0.1 mL). Estimations of equilibrium state and BPND were acquired[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight






Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥150 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: